Abstract
The clinical efficacy of biologic/targeted synthetic/biosimilar disease modifying antirheumatic drugs (b/ts/biosimilar DMARDs) in treating inflammatory arthritis is well documented, while the economic performance of these agents remains vague. This systematic review aims to identify the updated evidence of b/ts/biosimilar DMARDs cost-effectiveness in the management of inflammatory arthritis to inform prescribing and formulary listing decisions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
